ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT05172973

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05172973
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05172973. Non-randomized; no masking; primary purpose treatment. Start 2023-11-22 (actual); primary completion 2029-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
Condition
Aortic Valve Insufficiency
Condition
Aortic Valve Stenosis
Intervention (Device)
SAPIEN X4/X4S THV
Lead sponsor
Edwards Lifesciences (class: industry)

Record details

Record id
cardio:ct-nct05172973
Content hash
6680d5bc6b9d30e1868613550fba89d1f9a6b0615c39d63d18868503d2db4c48